Loading
Alexandria Venture Investments
Alexandria Venture Investments is the venture arm of Alexandria Real Estate Equities, the life science property company, and takes small, non-lead stakes across a large number of biotech start-ups, often tenants of its campuses, in oncology and other areas. Its web pages blocked automated access, so its own strategy and named cancer companies are unconfirmed.
Overview
Alexandria Venture Investments is the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE: ARE), the Pasadena-based life science real estate investment trust founded in January 1994 by Joel Marcus and Jerry Sudarsky (Wikipedia). The venture arm invests small, non-lead amounts across a large number of life science companies, many of them tenants of Alexandria campuses, spanning oncology and other therapeutic areas. The are.com venture pages returned an empty body or an Incapsula 'Request unsuccessful' block on every fetch attempt, so the platform's own description, founding year, strategy and named oncology portfolio companies could not be confirmed from a primary source.
Portfolio
14Portfolio (14)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| 858 Therapeutics San Diego, CA, US | Growth stage | biotech | Ovarian cancerBreast cancer (all types)Prostate cancer | Series B 2024, $50M |
| Bright Peak Therapeutics Allschwil, CH | Growth stage | biotech | Series C 2024, $90M | |
| Clasp Therapeutics Cambridge, MA, US | Startup | biotech | Series A 2024, $150M | |
| Dantari Thousand Oaks, CA, US | Wound down | biotech | HR-positive / HER2-negative breast cancerTriple-negative breast cancer (TNBC) | Series A 2022, $47M |
| Dewpoint Therapeutics Boston, MA, US | Growth stage | biotech | Gastric & gastro-oesophageal junction cancer | Series C 2022, $150M |
| Dispatch Bio Philadelphia, PA, US | Startup | cell therapy | Colorectal cancerGastric & gastro-oesophageal junction cancerOesophageal and junctional adenocarcinoma | Series A 2025 |
| Enlaza Therapeutics La Jolla, CA, US | Startup | biotech | Series A 2024, $100M | |
| Immunai New York, NY, US | Growth stage | ai software | none on record | |
| MOMA Therapeutics Cambridge, MA, US | Growth stage | biotech | Mismatch-repair deficient (MSI-high) colorectal cancerMismatch-repair-deficient endometrial cancer | Series B 2022, $150M |
| Neomorph San Diego, CA, US | Startup | biotech | Renal cell carcinoma | Series B 2026, $100M |
| Sidewinder Therapeutics San Diego, CA, US | Startup | biotech | Non-small-cell lung cancerHead and neck squamous cell carcinomaColorectal cancer | Series B 2026, $137M |
| Solu Therapeutics Boston, MA, US | Startup | biotech | Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasmsAcute myeloid leukaemia | Series A 2025, $41M |
| Solve Therapeutics San Diego, CA, US | Growth stage | biotech | Financing (round not named) 2025, $120M | |
| Stablix New York, NY, US | Startup | biotech | Series A 2021, $63M |
Notes
- Page fetched on 2026-09-10; founded year is the parent company's.
Connected
14Similar pages
- CompanyAmgen Ventures
Shares Enlaza Therapeutics and the tag corporate-venture.
- CompanyLeaps by Bayer
Shares Dewpoint Therapeutics and the tag corporate-venture.
- CompanyNovartis Venture Fund
Shares Sidewinder Therapeutics and the tag corporate-venture.
- CompanyJohnson & Johnson Innovation - JJDC
Shares Bright Peak Therapeutics and the tag corporate-venture.
- CompanyLongwood Fund
Shares Neomorph, Solu Therapeutics, Sidewinder Therapeutics.
- CompanyVersant Ventures
Shares Stablix, 858 Therapeutics, Bright Peak Therapeutics.
- CompanyCormorant Asset Management
Shares Stablix, 858 Therapeutics, MOMA Therapeutics.
- CompanySamsara BioCapital
Shares Enlaza Therapeutics, Dewpoint Therapeutics, Sidewinder Therapeutics.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
are.com · 1
Wikipedia · 1
A source that has moved or gone is reported by the weekly link check. /audit/